Superworth

Revolution Medicines free cash flow RVMD

Cash from operations less capital spending, by quarter and over the last twelve months, from 2019.

Last 12 months, to Jun 30, 2026
−$1.2B
Latest quarter, Q2 FY26
−$389.6M
Fiscal year 2025
−$913.7M

Revolution Medicines' free cash flow was −$1.2B over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$389.6M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$913.7Mn/a
FY2024−$567.7Mn/a
FY2023−$358.3Mn/a
FY2022−$235.2Mn/a
FY2021−$153.7Mn/a
FY2020−$103Mn/a
FY2019−$52.2Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$389.6Mn/a−$1.2B
Q1 FY26−$355.7Mn/a−$1.1B
Q4 FY25−$276.2Mn/a−$913.7M
Q3 FY25−$210.7Mn/a−$777.1M
Q2 FY25−$229.2Mn/a−$700.4M
Q1 FY25−$197.7Mn/a−$601.7M
Q4 FY24−$139.5Mn/a−$567.7M
Q3 FY24−$133.9Mn/a−$551.1M
Q2 FY24−$130.6Mn/a−$520.2M
Q1 FY24−$163.7Mn/a−$457.9M
Q4 FY23−$122.9Mn/a−$358.3M
Q3 FY23−$103Mn/a−$300.1M

Against its peers

Companies in Biotechnology nearest Revolution Medicines' size, closest first, today.

CompanyFree cash flow yield
RVMDRevolution Medicines−3.1%
ONCBeOne Medicines3.1%
ALNYAlnylam Pharmaceuticals2.6%
UTHRUnited Therapeutics4.3%
INCYIncyte8.2%
REGNRegeneron Pharmaceuticals4.5%
EXELExelixis7.3%
NBIXNeurocrine Biosciences6.0%
HALOHalozyme Therapeutics5.7%
VRTXVertex Pharmaceuticals2.9%
TECHBIO-TECHNE2.3%
Peer median4.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Revolution Medicines

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.